Literature DB >> 27482104

O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis.

Qinghua Zeng1, Rui-Xun Zhao2, Jianfeng Chen2, Yining Li2, Xiang-Dong Li2, Xiao-Long Liu2, Wei-Ming Zhang2, Cheng-Shi Quan3, Yi-Shu Wang3, Ying-Xian Zhai3, Jian-Wei Wang3, Mariam Youssef3, Rutao Cui4, Jiyong Liang5, Nicholas Genovese6, Louise T Chow7, Yu-Lin Li8, Zhi-Xiang Xu9.   

Abstract

High-risk human papillomaviruses (HPVs) are causative agents of anogenital cancers and a fraction of head and neck cancers. The mechanisms involved in the progression of HPV neoplasias to cancers remain largely unknown. Here, we report that O-linked GlcNAcylation (O-GlcNAc) and O-GlcNAc transferase (OGT) were markedly increased in HPV-caused cervical neoplasms relative to normal cervix, whereas O-GlcNAcase (OGA) levels were not altered. Transduction of HPV16 oncogene E6 or E6/E7 into mouse embryonic fibroblasts (MEFs) up-regulated OGT mRNA and protein, elevated the level of O-GlcNAc, and promoted cell proliferation while reducing cellular senescence. Conversely, in HPV-18-transformed HeLa cervical carcinoma cells, inhibition of O-GlcNAc with a low concentration of a chemical inhibitor impaired the transformed phenotypes in vitro. We showed that E6 elevated c-MYC via increased protein stability attributable to O-GlcNAcylation on Thr58. Reduction of HPV-mediated cell viability by a high concentration of O-GlcNAc inhibitor was partially rescued by elevated c-MYC. Finally, knockdown of OGT or O-GlcNAc inhibition in HeLa cells or in TC-1 cells, a mouse cell line transformed by HPV16 E6/E7 and activated K-RAS, reduced c-MYC and suppressed tumorigenesis and metastasis. Thus, we have uncovered a mechanism for HPV oncoprotein-mediated transformation. These findings may eventually aid in the development of effective therapeutics for HPV-associated malignancies by targeting aberrant O-GlcNAc.

Entities:  

Keywords:  HPV E6; HPV oncogenicity; O-linked GlcNAcylation; c-MYC; cervical cancer

Mesh:

Substances:

Year:  2016        PMID: 27482104      PMCID: PMC4995993          DOI: 10.1073/pnas.1606801113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

2.  O-GlcNAc regulates pluripotency and reprogramming by directly acting on core components of the pluripotency network.

Authors:  Hyonchol Jang; Tae Wan Kim; Sungho Yoon; Soo-Youn Choi; Tae-Wook Kang; Seon-Young Kim; Yoo-Wook Kwon; Eun-Jung Cho; Hong-Duk Youn
Journal:  Cell Stem Cell       Date:  2012-05-17       Impact factor: 24.633

3.  E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc.

Authors:  L Gewin; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc.

Authors:  Xuefeng Liu; Aleksandra Dakic; Renxiang Chen; Gary L Disbrow; Yiyu Zhang; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

5.  Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms.

Authors:  A Dellas; E Schultheiss; M R Leivas; H Moch; J Torhorst
Journal:  Anticancer Res       Date:  1998 Nov-Dec       Impact factor: 2.480

Review 6.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

7.  Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein.

Authors:  T Veldman; I Horikawa; J C Barrett; R Schlegel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.

Authors:  T Y Chou; G W Hart; C V Dang
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

9.  Glycosylation of the c-Myc transactivation domain.

Authors:  T Y Chou; C V Dang; G W Hart
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance.

Authors:  Xiaoyong Yang; Pat P Ongusaha; Philip D Miles; Joyce C Havstad; Fengxue Zhang; W Venus So; Jeffrey E Kudlow; Robert H Michell; Jerrold M Olefsky; Seth J Field; Ronald M Evans
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

View more
  22 in total

1.  O-GlcNAcylation reduces proximal tubule protein reabsorption and promotes proteinuria in spontaneously hypertensive rats.

Authors:  Rodrigo Pacheco Silva-Aguiar; Nathália C F Bezerra; Miguel C Lucena; Gabriela M Sirtoli; Roberto T Sudo; Gisele Zapata-Sudo; Christina M Takiya; Ana Acacia S Pinheiro; Wagner Barbosa Dias; Celso Caruso-Neves
Journal:  J Biol Chem       Date:  2018-06-28       Impact factor: 5.157

Review 2.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

Review 3.  Protein O-GlcNAcylation: emerging mechanisms and functions.

Authors:  Xiaoyong Yang; Kevin Qian
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-10       Impact factor: 94.444

4.  Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.

Authors:  Katharina Herzog; Simonetta Bandiera; Sophie Pernot; Catherine Fauvelle; Frank Jühling; Amélie Weiss; Anne Bull; Sarah C Durand; Béatrice Chane-Woon-Ming; Sébastien Pfeffer; Marion Mercey; Hervé Lerat; Jean-Christophe Meunier; Wolfgang Raffelsberger; Laurent Brino; Thomas F Baumert; Mirjam B Zeisel
Journal:  Gut       Date:  2019-05-10       Impact factor: 31.793

5.  Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines.

Authors:  Karin Hoppe-Seyler; Anja Honegger; Felicitas Bossler; Jasmin Sponagel; Julia Bulkescher; Claudia Lohrey; Felix Hoppe-Seyler
Journal:  Oncotarget       Date:  2017-11-15

6.  LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism.

Authors:  Q Zeng; J Chen; Y Li; K D Werle; R-X Zhao; C-S Quan; Y-S Wang; Y-X Zhai; J-W Wang; M Youssef; R Cui; J Liang; N Genovese; L T Chow; Y-L Li; Z-X Xu
Journal:  Oncogene       Date:  2016-08-22       Impact factor: 9.867

7.  LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.

Authors:  Yi-Shu Wang; Jianfeng Chen; Fengmei Cui; Huibo Wang; Shuai Wang; Wei Hang; Qinghua Zeng; Cheng-Shi Quan; Ying-Xian Zhai; Jian-Wei Wang; Xiang-Feng Shen; Yong-Ping Jian; Rui-Xun Zhao; Kaitlin D Werle; Rutao Cui; Jiyong Liang; Yu-Lin Li; Zhi-Xiang Xu
Journal:  Oncotarget       Date:  2016-11-08

8.  Proteomic analysis of the OGT interactome: novel links to epithelial-mesenchymal transition and metastasis of cervical cancer.

Authors:  Jie Gao; Yang Yang; Rongfang Qiu; Kai Zhang; Xu Teng; Ruiqiong Liu; Yan Wang
Journal:  Carcinogenesis       Date:  2018-10-08       Impact factor: 4.944

9.  O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity.

Authors:  Eunah Kim; Jeong Gu Kang; Min Jueng Kang; Jae Hyung Park; Yeon Jung Kim; Tae Hyun Kweon; Han-Woong Lee; Eek-Hoon Jho; Yong-Ho Lee; Seung-Il Kim; Eugene C Yi; Hyun Woo Park; Won Ho Yang; Jin Won Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

10.  Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.

Authors:  Wei Hang; Zhi-Xian Yin; Gang Liu; Qinghua Zeng; Xiang-Feng Shen; Qian-Hui Sun; Dong-Dong Li; Yong-Ping Jian; Yang-He Zhang; Yi-Shu Wang; Cheng-Shi Quan; Rui-Xun Zhao; Yu-Lin Li; Zhi-Xiang Xu
Journal:  Oncogene       Date:  2018-01-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.